- cafead   Jan 11, 2023 at 11:13: PM
via Ionis Pharmaceuticals once had AstraZeneca involved with and spied a bright future for PCSK9 inhibitor ION449. Now, after the U.K. pharma backed out last year, CEO Brett Monia, Ph.D., thinks the drug may have missed its shot.
article source
article source